| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | cla |
| Uniprot No | Q8WTV0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 33-443aa |
| 氨基酸序列 | PSLIKQQVLKNVRIDPSSLSFNMWKEIPIPFYLSVYFFDVMNPSEILKGEKPQVRERGPYVYREFRHKSNITFNNNDTVSFLEYRTFQFQPSKSHGSESDYIVMPNILVLGAAVMMENKPMTLKLIMTLAFTTLGERAFMNRTVGEIMWGYKDPLVNLINKYFPGMFPFKDKFGLFAELNNSDSGLFTVFTGVQNISRIHLVDKWNGLSKVDFWHSDQCNMINGTSGQMWPPFMTPESSLEFYSPEACRSMKLMYKESGVFEGIPTYRFVAPKTLFANGSIYPPNEGFCPCLESGIQNVSTCRFSAPLFLSHPHFLNADPVLAEAVTGLHPNQEAHSLFLDIHPVTGIPMNCSVKLQLSLYMKSVAGIGQTGKIEPVVLPLLWFAESGAMEGETLHTFYTQLVLMPKVMHY |
| 预测分子量 | 62.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于共轭亚油酸(CLA)重组蛋白相关研究的示例文献摘要(请注意，以下内容为模拟示例，实际文献需通过学术数据库核实)：
---
1. **文献名称**：*Production of Conjugated Linoleic Acid by Recombinant Escherichia coli Expressing Linoleate Isomerase*
**作者**：Lee, J.H., Kim, Y.B., & Park, H.Y.
**摘要**：研究通过基因重组技术在大肠杆菌中表达亚油酸异构酶，成功实现共轭亚油酸(CLA)的生物合成。实验优化了发酵条件，显著提高了CLA产量，为工业化生产提供了潜在方案。
2. **文献名称**：*Engineering a Recombinant Bifidobacterium Strain for CLA Production in Fermented Dairy Products*
**作者**：Rossi, F., & Marzano, M.
**摘要**：通过构建重组双歧杆菌工程菌株，使其表达CLA合成关键酶，探究其在乳制品发酵中的应用。结果显示，该菌株可高效转化乳脂中的亚油酸为CLA，提升产品营养价值。
3. **文献名称**：*Structural and Functional Analysis of a Recombinant CLA-Binding Protein from Lactobacillus plantarum*
**作者**：Zhang, Q., et al.
**摘要**：从植物乳杆菌中克隆并表达了一种新型CLA结合蛋白，通过X射线晶体学解析其三维结构，揭示了其与CLA特异性结合的分子机制，为开发CLA靶向递送系统奠定基础。
4. **文献名称**：*Enhancing CLA Biosynthesis via Co-expression of Recombinant Fatty Acid Desaturases and Thioesterases*
**作者**：Wang, L., & Chen, W.
**摘要**：通过在大肠杆菌中共表达重组脂肪酸脱饱和酶和硫酯酶，优化CLA合成途径的代谢通量，显著提高CLA产率，为微生物合成功能性脂质提供了新策略。
---
**提示**：实际研究中，建议通过PubMed、Web of Science或SciHub等平台，以关键词“recombinant protein conjugated linoleic acid”或“CLA biosynthesis recombinant enzyme”检索最新文献。部分研究可能涉及酶工程、代谢工程或食品科学领域。
**Background of CLA Recombinant Proteins**
CLA (Chimeric Antigen Receptor) recombinant proteins are engineered molecules central to advancing adoptive cell therapies, particularly CAR-T cell therapy. Originating in the late 1980s, CAR technology combines antigen-binding domains (often derived from antibodies) with intracellular signaling domains to reprogram immune cells, enabling targeted recognition of cancer cells. Early CAR designs (first-generation) incorporated single-chain variable fragments (scFv) fused to CD3ζ signaling domains but showed limited efficacy due to insufficient T-cell activation. Subsequent generations integrated co-stimulatory domains (e.g., CD28. 4-1BB) to enhance persistence and cytotoxicity, revolutionizing outcomes in hematologic malignancies like B-cell lymphoma and leukemia.
Recombinant protein techniques enable precise assembly of CAR components. Using gene cloning, scFvs are linked to transmembrane and signaling domains, which are then expressed in viral vectors (e.g., lentivirus) for delivery into patient-derived T cells. This ex vivo engineering creates CAR-T cells capable of recognizing specific tumor antigens (e.g., CD19. BCMA).
Recent advancements focus on improving safety and versatility. "Armored" CARs incorporate cytokine-secreting modules (e.g., IL-12) to counteract immunosuppressive microenvironments, while logic-gated CARs aim to enhance specificity for solid tumors. Universal CARs (UCAR-T) using gene-editing tools like CRISPR-Cas9 seek to reduce manufacturing complexity.
Despite successes, challenges persist, including cytokine release syndrome (CRS), antigen escape, and limited efficacy in solid tumors. Ongoing research explores multi-target CARs, switchable systems, and combination therapies. CLA recombinant proteins thus represent a transformative platform bridging immunology, genetic engineering, and oncology, with potential to redefine precision medicine.
×
